Latest Brainstorm Cell Ther (BCLI) Headlines
BrainStorm Cell Therapeutics awarded USD600,000 non-dilutive grant
M2 - Wed Feb 26, 5:59AM CST
Stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI), based in the US and Israel, disclosed on Tuesday the receipt of an additional USD600,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014.
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
Marketwire - Tue Feb 25, 8:15AM CST
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that BrainStorm Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014 in the amount of $600,000. The grant is intended to support BrainStorm's clinical development for its innovative stem cell therapy candidate NurOwn(TM).
BrainStorm Issues Annual Letter to Shareholders
Business Wire - Tue Feb 04, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today issued a Letter to Shareholders from its President, Mr. Chaim Lebovits, summarizing the company's major developments in 2013.
BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology Patent
Business Wire - Mon Feb 03, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Mesenchymal Stem Cells for the Treatment of CNS Diseases" (serial number 12/994,761) patent application.
BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing
Business Wire - Wed Jan 29, 7:00AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo's Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The other two sites slated for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.
BrainStorm Hosting a Conference Call with Clinical Trial Advisors in Israel, US and Brazil to Update Shareholders on Current Developments
Business Wire - Wed Jan 15, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Thursday, January 30, 2014 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST).
BrainStorm Cell Therapeutics awarded US Patent Office's Notice of Allowance for stem cell technology
M2 - Tue Jan 14, 4:51AM CST
Biotechnology company BrainStorm Cell Therapeutics (OTC BB:BCLI) reported on Monday the receipt of a Notice of Allowance for its 'Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases'.
BrainStorm Receives United States Patent Office Notice of Allowance for Its Stem Cell Technology
Business Wire - Mon Jan 13, 8:42AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.
BrainStorm Receives Notice of Allowance to Grant European Patent Covering its Stem Cells for the Treatment of CNS Diseases
Business Wire - Wed Jan 08, 8:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received notification from the European Patent Office (EPO) of its intention to grant the company's patent application No. EP06766101.7 entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases."
Significant Clinical Findings on ALS Patient Treated with BrainStorm's NurOwn Featured in "Muscle and Nerve"
Business Wire - Mon Jan 06, 7:30AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced the upcoming publication of a case report on an individual patient treated with the company's NurOwn(TM) cell therapy in "Muscle & Nerve" (John Wiley & Sons). The report, which looked at one patient diagnosed with both Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS) showed significant improvements in both cognitive and motor function following initial and repeat treatments with NurOwn.
2013 Report on the International Stem Cells Market - Includes Forecast to 2018
M2 - Wed Dec 18, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/732xpm/stem_cells_market) has announced the addition of the "2013 Report on the International Stem Cells Market - Includes Forecast to 2018" report to their offering. "2013 Report on the International Stem Cells Market - Includes Forecast to 2018", highlights the market shares of key players in 2011. The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered. The global stem cells market is categorized into the following segments: - Stem Cells Market by Products - Adult Stem Cells - Hematopoietic Stem Cells - Mesenchymal Stem Cells - Neuronal Stem Cells - Dental Stem Cells - Umbilical Cord Stem Cells - Human Embryonic Stem Cells - Induced Pluripotent Stem Cells - Natural Rosette Cells - Very Small Embryonic Like Stem Cells - Stem Cells Market by Technology - Cell Acquisition - Bone Marrow Harvest - Apheresis - Umbilical Blood Cord - Cell Production - Therapeutic Cloning - In Vitro Fertilization - Isolation - Cell Culture - Cryopreservation - Expansion and Sub-Culture - Stem Cells Market by Applications - Regenerative Medicine - Neurological Disorders - Orthopedics - Cancer - Hematological disorders - Cardiovascular diseases Stem Cells Market by Geography - North America - Europe - Asia - Rest of the World (RoW) Key Topics Covered: 1 Preface 1.1 Report Description 1.2 Research Methodology 2 Executive Summary 3 Market Overview 3.1 Market Trends and Future Outlook 3.2 Market Dynamics 3.3 Market Attractiveness 4 Global Stem Cells Market, By Products 4.1 Market Segmentation: Global Stem Cells Market, By Products 4.2 Overview 4.3 Adult Stem Cells Market, 2010 - 2018 (USD Billion) 4.4 Human Embryonic Stem Cells Market, 2010 - 2018 (USD Billion) 4.5 Induced Pluripotent Stem Cells Market, 2010 - 2018 (USD Billion) 4.6 Rat Neural Stem Cells Market, 2010 - 2018 (USD Billion) 4.7 Very Small Embryonic-Like Stem Cells Market, 2010 - 2018 (USD Billion) 5 Global Stem Cells Market, By Technology 6 Global Stem Cells Market, By Application 7 Global Stem Cells Market, By Geography 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Advanced Cell Technology - Angel Biotechnology - Bioheart - Biotime Inc. - Brainstorm Cell Therapeutics - California Stem Cell Inc. - Celgene Corporation Inc. - Cellartis AB - Cellular Engineering Technologies - Cytori Therapeutics Inc. - Osiris Therapeutics - Stemcelltechnologies Inc. For more information visit http://www.researchandmarkets.com/research/73...lls_market
Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets
BrainStorm Cell Therapeutics Inc wins USD800,000 OCS grant in Israel
M2 - Thu Dec 12, 3:29AM CST
Adult stem cell company BrainStorm Cell Therapeutics Inc (OTC BB:BCLI) reported on Wednesday the receipt of a USD800,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014.
BrainStorm Receives $800,000 Non-Dilutive Grant from Israel's Office of the Chief Scientist
Business Wire - Wed Dec 11, 8:00AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a $800,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014. The grant is intended to support BrainStorm's clinical and product development for its innovative stem cell therapy candidate NurOwn(TM).
Preliminary Findings of BrainStorm's Phase IIa Study Reported as "Extremely Optimistic"
Business Wire - Tue Dec 10, 7:57AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Prof. Dimitrios Karussis, Principal Investigator of the Company's clinical trials at Hadassah Medical Center in Jerusalem, presented some of his preliminary findings from the ongoing Phase IIa dose-escalating trial evaluating the company's NurOwn(TM) technology, at the 24th International Symposium on ALS/MND last week in Milan, Italy.
BrainStorm Cell Therapeutics Presents at the 24th International Symposium on ALS/MND
Business Wire - Thu Dec 05, 8:43AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Prof. Dimitrios Karussis, Principal Investigator of the Company's clinical trials at Hadassah Medical Center in Jerusalem, will deliver an oral presentation at the 24th International Symposium on ALS/MND being held this week in Milan, Italy (http://bit.ly/IFCIdS).
BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Positive Company Developments
Business Wire - Tue Nov 12, 8:00AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, November 19, 2013 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr. Chaim Lebovits, President and Principal Executive Officer, will update shareholders on the latest positive company developments. The call will be conducted in English, with Q&A in both English and Hebrew.
Global Stem Cells Market Report 2013-2018: Adult Stem Cells, Human Embryonic Stem Cells and Other Stem Cells
M2 - Thu Oct 17, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c523lv/stem_cells_market) has announced the addition of the "Global Stem Cells Market Report 2013-2018" report to their offering. Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018 The market by products is segmented into three sub-types, namely adult stem cells, human embryonic stem cells and other type of stem cells. Adult stem cells are further segmented into hematopoietic stem cells, mesenchymal stem cells, neuronal stem cells, dental stem cells and umbilical cord stem cells. The other types of stem cells include induced pluripotent stem cells, natural rosette cells and very small embryonic like stem cells. The report highlights the market shares of key players in 2011. The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Stem Cells Market, By Products Chapter 5 Global Stem Cells Market, By Technology Chapter 6 Global Stem Cells Market, By Application Chapter 7 Global Stem Cells Market, By Geography Chapter 8 Competitive Landscape Chapter 9 Company Profiles - Advanced Cell Technology - Angel Biotechnology - Bioheart - Biotime Inc. - Brainstorm Cell Therapeutics - California Stem Cell Inc. - Celgene Corporation Inc. - Cellartis AB - Cellular Engineering Technologies - Cytori Therapeutics Inc. - Osiris Therapeutics - Stemcelltechnologies Inc. For more information visit http://www.researchandmarkets.com/research/c5...lls_market
BrainStorm to Initiate Study for Multiple Sclerosis at Hadassah Medical Center
Business Wire - Tue Oct 15, 8:30AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will initiate a pre-clinical study for Multiple Sclerosis (MS) at the Hebrew University Hadassah Medical Center's SPF-grade animal laboratory in Jerusalem. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University.
BrainStorm Cell Therapeutics awarded USD600,000 non-dilutive grant
M2 - Wed Feb 26, 5:59AM CST
Stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI), based in the US and Israel, disclosed on Tuesday the receipt of an additional USD600,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014.
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
Marketwire - Tue Feb 25, 8:15AM CST
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that BrainStorm Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014 in the amount of $600,000. The grant is intended to support BrainStorm's clinical development for its innovative stem cell therapy candidate NurOwn(TM).
BrainStorm Issues Annual Letter to Shareholders
Business Wire - Tue Feb 04, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today issued a Letter to Shareholders from its President, Mr. Chaim Lebovits, summarizing the company's major developments in 2013.
BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology Patent
Business Wire - Mon Feb 03, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Mesenchymal Stem Cells for the Treatment of CNS Diseases" (serial number 12/994,761) patent application.
BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing
Business Wire - Wed Jan 29, 7:00AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo's Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The other two sites slated for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.
BrainStorm Hosting a Conference Call with Clinical Trial Advisors in Israel, US and Brazil to Update Shareholders on Current Developments
Business Wire - Wed Jan 15, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Thursday, January 30, 2014 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST).
BrainStorm Cell Therapeutics awarded US Patent Office's Notice of Allowance for stem cell technology
M2 - Tue Jan 14, 4:51AM CST
Biotechnology company BrainStorm Cell Therapeutics (OTC BB:BCLI) reported on Monday the receipt of a Notice of Allowance for its 'Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases'.
BrainStorm Receives United States Patent Office Notice of Allowance for Its Stem Cell Technology
Business Wire - Mon Jan 13, 8:42AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.
BrainStorm Receives Notice of Allowance to Grant European Patent Covering its Stem Cells for the Treatment of CNS Diseases
Business Wire - Wed Jan 08, 8:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received notification from the European Patent Office (EPO) of its intention to grant the company's patent application No. EP06766101.7 entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases."
Significant Clinical Findings on ALS Patient Treated with BrainStorm's NurOwn Featured in "Muscle and Nerve"
Business Wire - Mon Jan 06, 7:30AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced the upcoming publication of a case report on an individual patient treated with the company's NurOwn(TM) cell therapy in "Muscle & Nerve" (John Wiley & Sons). The report, which looked at one patient diagnosed with both Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS) showed significant improvements in both cognitive and motor function following initial and repeat treatments with NurOwn.
2013 Report on the International Stem Cells Market - Includes Forecast to 2018
M2 - Wed Dec 18, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/732xpm/stem_cells_market) has announced the addition of the "2013 Report on the International Stem Cells Market - Includes Forecast to 2018" report to their offering. "2013 Report on the International Stem Cells Market - Includes Forecast to 2018", highlights the market shares of key players in 2011. The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered. The global stem cells market is categorized into the following segments: - Stem Cells Market by Products - Adult Stem Cells - Hematopoietic Stem Cells - Mesenchymal Stem Cells - Neuronal Stem Cells - Dental Stem Cells - Umbilical Cord Stem Cells - Human Embryonic Stem Cells - Induced Pluripotent Stem Cells - Natural Rosette Cells - Very Small Embryonic Like Stem Cells - Stem Cells Market by Technology - Cell Acquisition - Bone Marrow Harvest - Apheresis - Umbilical Blood Cord - Cell Production - Therapeutic Cloning - In Vitro Fertilization - Isolation - Cell Culture - Cryopreservation - Expansion and Sub-Culture - Stem Cells Market by Applications - Regenerative Medicine - Neurological Disorders - Orthopedics - Cancer - Hematological disorders - Cardiovascular diseases Stem Cells Market by Geography - North America - Europe - Asia - Rest of the World (RoW) Key Topics Covered: 1 Preface 1.1 Report Description 1.2 Research Methodology 2 Executive Summary 3 Market Overview 3.1 Market Trends and Future Outlook 3.2 Market Dynamics 3.3 Market Attractiveness 4 Global Stem Cells Market, By Products 4.1 Market Segmentation: Global Stem Cells Market, By Products 4.2 Overview 4.3 Adult Stem Cells Market, 2010 - 2018 (USD Billion) 4.4 Human Embryonic Stem Cells Market, 2010 - 2018 (USD Billion) 4.5 Induced Pluripotent Stem Cells Market, 2010 - 2018 (USD Billion) 4.6 Rat Neural Stem Cells Market, 2010 - 2018 (USD Billion) 4.7 Very Small Embryonic-Like Stem Cells Market, 2010 - 2018 (USD Billion) 5 Global Stem Cells Market, By Technology 6 Global Stem Cells Market, By Application 7 Global Stem Cells Market, By Geography 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Advanced Cell Technology - Angel Biotechnology - Bioheart - Biotime Inc. - Brainstorm Cell Therapeutics - California Stem Cell Inc. - Celgene Corporation Inc. - Cellartis AB - Cellular Engineering Technologies - Cytori Therapeutics Inc. - Osiris Therapeutics - Stemcelltechnologies Inc. For more information visit http://www.researchandmarkets.com/research/73...lls_market
Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets
BrainStorm Cell Therapeutics Inc wins USD800,000 OCS grant in Israel
M2 - Thu Dec 12, 3:29AM CST
Adult stem cell company BrainStorm Cell Therapeutics Inc (OTC BB:BCLI) reported on Wednesday the receipt of a USD800,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014.
BrainStorm Receives $800,000 Non-Dilutive Grant from Israel's Office of the Chief Scientist
Business Wire - Wed Dec 11, 8:00AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a $800,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014. The grant is intended to support BrainStorm's clinical and product development for its innovative stem cell therapy candidate NurOwn(TM).
Preliminary Findings of BrainStorm's Phase IIa Study Reported as "Extremely Optimistic"
Business Wire - Tue Dec 10, 7:57AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Prof. Dimitrios Karussis, Principal Investigator of the Company's clinical trials at Hadassah Medical Center in Jerusalem, presented some of his preliminary findings from the ongoing Phase IIa dose-escalating trial evaluating the company's NurOwn(TM) technology, at the 24th International Symposium on ALS/MND last week in Milan, Italy.
BrainStorm Cell Therapeutics Presents at the 24th International Symposium on ALS/MND
Business Wire - Thu Dec 05, 8:43AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Prof. Dimitrios Karussis, Principal Investigator of the Company's clinical trials at Hadassah Medical Center in Jerusalem, will deliver an oral presentation at the 24th International Symposium on ALS/MND being held this week in Milan, Italy (http://bit.ly/IFCIdS).
BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Positive Company Developments
Business Wire - Tue Nov 12, 8:00AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, November 19, 2013 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr. Chaim Lebovits, President and Principal Executive Officer, will update shareholders on the latest positive company developments. The call will be conducted in English, with Q&A in both English and Hebrew.
Global Stem Cells Market Report 2013-2018: Adult Stem Cells, Human Embryonic Stem Cells and Other Stem Cells
M2 - Thu Oct 17, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c523lv/stem_cells_market) has announced the addition of the "Global Stem Cells Market Report 2013-2018" report to their offering. Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018 The market by products is segmented into three sub-types, namely adult stem cells, human embryonic stem cells and other type of stem cells. Adult stem cells are further segmented into hematopoietic stem cells, mesenchymal stem cells, neuronal stem cells, dental stem cells and umbilical cord stem cells. The other types of stem cells include induced pluripotent stem cells, natural rosette cells and very small embryonic like stem cells. The report highlights the market shares of key players in 2011. The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Stem Cells Market, By Products Chapter 5 Global Stem Cells Market, By Technology Chapter 6 Global Stem Cells Market, By Application Chapter 7 Global Stem Cells Market, By Geography Chapter 8 Competitive Landscape Chapter 9 Company Profiles - Advanced Cell Technology - Angel Biotechnology - Bioheart - Biotime Inc. - Brainstorm Cell Therapeutics - California Stem Cell Inc. - Celgene Corporation Inc. - Cellartis AB - Cellular Engineering Technologies - Cytori Therapeutics Inc. - Osiris Therapeutics - Stemcelltechnologies Inc. For more information visit http://www.researchandmarkets.com/research/c5...lls_market
BrainStorm to Initiate Study for Multiple Sclerosis at Hadassah Medical Center
Business Wire - Tue Oct 15, 8:30AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will initiate a pre-clinical study for Multiple Sclerosis (MS) at the Hebrew University Hadassah Medical Center's SPF-grade animal laboratory in Jerusalem. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University.
